An in vivo porcine evaluation of the safety, bioavailability, and tissue penetration of a ketorolac drug-eluting ureteral stent designed to improve comfort

Journal of Endourology

Volumn 24, Issue 6, 2010, Pages 1023-1029

  Chew, Ben H ^a   Davoudi, Hamid ^b   Li, Jamie ^b   Denstedt, John D ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BOSTON SCIENTIFIC CORPORATION   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KETOROLAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BLADDER; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; DRUG TISSUE LEVEL; DRUG URINE LEVEL; DYSURIA; FLANK PAIN; HEMATURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; KIDNEY PARENCHYMA; LIVER; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STOMACH ULCER; SWINE; TREATMENT DURATION; URETER; URETER STENT; URETHRA;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; KETOROLAC; SUS SCROFA; TISSUE DISTRIBUTION; URETER;

EID: 77953636579     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2009.0523     Document Type: Article

References (12)

1. Joshi HB, Okeke A, Newns N, et al. Characterization of urinary symptoms in patients with ureteral stents. Urology 2002;59: 511-516.
2. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109: 1942-1947.
3. Beiko DT, Watterson JD, Knudsen BE, et al. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol 2004;18: 723-730.
4. Selmy GI, Hassouna MM, Bégin LR, et al. Long-term effects of ureteric stent after ureteric dilation. J Urol 1993;150: 1984-1989.
5. Marx M, Bettmann MA, Bridge S, et al. The effects of various indwelling ureteral catheter materials on the normal canine ureter. J Urol 1988;139: 180-185.
6. Hao P, Li W, Song C, et al. Clinical evaluation of doublepigtail stent in patients with upper urinary tract diseases: Report of 2685 cases. J Endourol 2008;22: 65-70.
7. Joshi HB, Chitale SV, Nagarajan M, et al. A prospective randomized single-blind comparison of ureteral stents composed of firm and soft polymer. J Urol 2005;174: 2303-2306.
8. Damiano R, Autorino R, De Sio M, et al. Effect of tamsulosin in preventing ureteral stent-related morbidity: A prospective study. J Endourol 2008;22: 651-656.
9. Nakada SY. Tamsulosin: Ureteric motility. BJU Int 2008;101: 1061-1062.
10. Han Y, Wang S, Jing Q, et al. Comparison of long-term efficacy of the paclitaxel-eluting stent versus the bare-metal stent for treatment of unprotected left main coronary artery disease. Am J Cardiol 2009;103: 194-198.
11. Perlmutter A, Miller L, Trimble LA, et al. Toradol, an NSAID used for renal colic, decreases renal perfusion and ureteral pressure in a canine model of unilateral ureteral obstruction. J Urol 1993;149: 926-930.
12. Wen CC, Coyle TL, Jerde TJ, Nakada SY. Ketorolac effectively inhibits ureteral contractility in vitro. J Endourol 2008;22: 739-742.